|
1
|
Pawłowska A, Suszczyk D, Okła K,
Barczyński B, Kotarski J and Wertel I: Immunotherapies based on
PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment. Clin Exp
Immunol. 195:334–344. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moufarrij S, Dandapani M, Arthofer E,
Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A and Chiappinelli
KB: Epigenetic therapy for ovarian cancer: Promise and progress.
Clin Epigenetics. 11:72019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Christie EL and Bowtell DDL: Acquired
chemotherapy resistance in ovarian cancer. Ann Oncol. 28 (Suppl
8):viii13–viii15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilson MK, Friedlander ML, Joly F and Oza
AM: A systematic review of health-related quality of life reporting
in ovarian cancer phase III clinical trials: Room to improve.
Oncologist. 23:203–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao H, Bi T, Qu Z, Jiang J, Cui S and
Wang Y: Expression of miR-224-5p is associated with the original
cisplatin resistance of ovarian papillary serous carcinoma. Oncol
Rep. 32:1003–1012. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Young MJ, Hsu KC, Lin TE, Chang WC and
Hung JJ: The role of ubiquitin-specific peptidases in cancer
progression. J Biomed Sci. 26:422019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vlasschaert C, Xia X, Coulombe J and Gray
DA: Evolution of the highly networked deubiquitinating enzymes
USP4, USP15, and USP11. BMC Evol Biol. 15:2302015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Satija YK, Bhardwaj A and Das S: A
portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Int J Cancer. 133:2759–2768. 2013.PubMed/NCBI
|
|
9
|
Kee Y and Huang TT: Role of
deubiquitinating enzymes in DNA repair. Mol Cell Biol. 36:524–544.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu S, Liu X, Wang H, Zhou Q, Liang Y, Sui
A, Yao R, Zhao B and Sun M: Lentiviral vector-mediated
doxycycline-inducible USP39 shRNA or cDNA expression in
triple-negative breast cancer cells. Oncol Rep. 33:2477–2483. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan X, Sun X, Shi X, Jiang C, Yu D, Zhang
W, Guan W, Zhou J, Wu Y, Qiu Y and Ding Y: USP39 promotes the
growth of human hepatocellular carcinoma in vitro and in
vivo. Oncol Rep. 34:823–832. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lawson AP, Long MJC, Coffey RT, Qian Y,
Weerapana E, El Oualid F and Hedstrom L: Naturally occurring
isothiocyanates exert anticancer effects by inhibiting
deubiquitinating enzymes. Cancer Res. 75:5130–5142. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Xie C, Wang X, Huang Y, Gao S, Lu
J, Lu Y and Zhang S: Aberrant USP11 expression regulates NF90 to
promote proliferation and metastasis in hepatocellular carcinoma.
Am J Cancer Res. 10:1416–1428. 2020.PubMed/NCBI
|
|
14
|
Imai S, Mamiya T, Tsukada A, Sakai Y,
Mouri A, Nabeshima T and Ebihara S: Ubiquitin-specific peptidase 46
(Usp46) regulates mouse immobile behavior in the tail suspension
test through the GABAergic system. PLoS One. 7:e390842012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kushima I, Aleksic B, Ito Y, Nakamura Y,
Nakamura K, Mori N, Kikuchi M, Inada T, Kunugi H, Nanko S, et al:
Association study of ubiquitin-specific peptidase 46 (USP46) with
bipolar disorder and schizophrenia in a Japanese population. J Hum
Genet. 55:133–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen YA, Stevens PD, Gasser ML, Andrei R
and Gao T: Downregulation of PHLPP expression contributes to
hypoxia-induced resistance to chemotherapy in colon cancer cells.
Mol Cell Biol. 33:4594–4605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Stevens PD, Yang H, Gulhati P, Wang
W, Evers BM and Gao T: The deubiquitination enzyme USP46 functions
as a tumor suppressor by controlling PHLPP-dependent attenuation of
Akt signaling in colon cancer. Oncogene. 32:471–478. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Chen T, Li X, Yan W, Lou Y, Liu Z,
Chen H and Cui Z: USP39 promotes ovarian cancer malignant
phenotypes and carboplatin chemoresistance. Int J Oncol.
55:277–288. 2019.PubMed/NCBI
|
|
19
|
Bayraktar S, Gutierrez Barrera AM, Liu D,
Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans
F and Arun B: USP-11 as a predictive and prognostic factor
following neoadjuvant therapy in women with breast cancer. Cancer
J. 19:10–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spassov DS and Jurecic R: The PUF family
of RNA-binding proteins: Does evolutionarily conserved structure
equal conserved function? IUBMB Life. 55:359–366. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cao Q, Padmanabhan K and Richter JD:
Pumilio 2 controls translation by competing with eIF4E for 7-methyl
guanosine cap recognition. RNA. 16:221–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Naudin C, Hattabi A, Michelet F,
Miri-Nezhad A, Benyoucef A, Pflumio F, Guillonneau F, Fichelson S,
Vigon I, Dusanter-Fourt I and Lauret E: PUMILIO/FOXP1 signaling
drives expansion of hematopoietic stem/progenitor and leukemia
cells. Blood. 129:2493–2506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Li C, Chen J, Liu P, Cui Y, Zhou X,
Li H and Zu X: High expression of long noncoding RNA NORAD
indicates a poor prognosis and promotes clinical progression and
metastasis in bladder cancer. Urol Oncol. 36:310.e15–310.e22. 2018.
View Article : Google Scholar
|
|
24
|
Daly MB, Pal T, Berry MP, Buys SS, Dickson
P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, et
al: Genetic/familial high-risk assessment: Breast, ovarian, and
pancreatic, version 2.2021, NCCN clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 19:77–102. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ,
Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in
stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao L, Huang L, Zhang J, Fan J, He F,
Zhao X, Wang H, Liu Q, Shi D, Ni N, et al: The inhibition of BRAF
activity sensitizes chemoresistant human ovarian cancer cells to
paclitaxel-induced cytotoxicity and tumor growth inhibition. Am J
Transl Res. 12:8084–8098. 2020.PubMed/NCBI
|
|
29
|
Martincuks A, Li PC, Zhao Q, Zhang C, Li
YJ, Yu H and Rodriguez-Rodriguez L: CD44 in ovarian cancer
progression and therapy resistance-a critical role for STAT3. Front
Oncol. 10:5896012020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun H, Wang H and Wang X, Aoki Y and Wang
X, Yang Y, Cheng X, Wang Z and Wang X: Aurora-A/SOX8/FOXK1
signaling axis promotes chemoresistance via suppression of cell
senescence and induction of glucose metabolism in ovarian cancer
organoids and cells. Theranostics. 10:6928–6945. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Z, Qu L, Zhong H, Xu K, Qiu X and Wang
E: Low expression of Mig-6 is associated with poor survival outcome
in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation
of Bcl-2. Oncol Rep. 31:1707–1714. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo Q, Dong B, Nan F, Guan D and Zhang Y:
5-Aminolevulinic acid photodynamic therapy in human cervical cancer
via the activation of microRNA-143 and suppression of the Bcl-2/Bax
signaling pathway. Mol Med Rep. 14:544–550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang R, Shi H, Ren F, Li X, Zhang M, Feng
W and Jia Y: Knockdown of MACC1 expression increases cisplatin
sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Oncol Rep. 35:2466–2472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feng X, Liu N, Deng S, Zhang D, Wang K and
Lu M: miR-199a modulates cisplatin resistance in ovarian cancer by
targeting Hif1α. Onco Targets Ther. 10:5899–5906. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xie J, Lin W, Huang L, Xu N, Xu A, Chen B,
Watanabe M, Liu C and Huang P: Bufalin suppresses the proliferation
and metastasis of renal cell carcinoma by inhibiting the
PI3K/Akt/mTOR signaling pathway. Oncol Lett. 16:3867–3873.
2018.PubMed/NCBI
|
|
36
|
Liu F, Shangli Z and Hu Z: CAV2 promotes
the growth of renal cell carcinoma through the EGFR/PI3K/Akt
pathway. Onco Targets Ther. 11:6209–6216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Smialek MJ, Ilaslan E, Sajek MP and
Jaruzelska J: Role of PUM RNA-binding proteins in cancer. Cancers
(Basel). 13:1292021. View Article : Google Scholar
|
|
38
|
Galgano A, Forrer M, Jaskiewicz L, Kanitz
A, Zavolan M and Gerber AP: Comparative analysis of mRNA targets
for human PUF-family proteins suggests extensive interaction with
the miRNA regulatory system. PLoS One. 3:e31642008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Martin-Broto J, Redondo A, Valverde C, Vaz
MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A,
Marcilla D, et al: Gemcitabine plus sirolimus for relapsed and
progressing osteosarcoma patients after standard chemotherapy: A
multicenter, single-arm phase II trial of Spanish group for
research on sarcoma (GEIS). Ann Oncol. 28:2994–2999. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Follwaczny P, Schieweck R, Riedemann T,
Demleitner A, Straub T, Klemm AH, Bilban M, Sutor B, Popper B and
Kiebler MA: Pumilio2-deficient mice show a predisposition for
epilepsy. Dis Model Mech. 10:1333–1342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ginter-Matuszewska B, Kusz K, Spik A,
Grzeszkowiak D, Rembiszewska A, Kupryjanczyk J and Jaruzelska J:
NANOS1 and PUMILIO2 bind microRNA biogenesis factor GEMIN3, within
chromatoid body in human germ cells. Histochem Cell Biol.
136:279–287. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang M, Chen D, Xia J, Han W, Cui X,
Neuenkirchen N, Hermes G, Sestan N and Lin H: Post-transcriptional
regulation of mouse neurogenesis by Pumilio proteins. Genes Dev.
31:1354–1369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Y, Sun W, Yang J, Yang L, Li C, Liu
H, Liu X and Jiao B: PUM2 promotes glioblastoma cell proliferation
and migration via repressing BTG1 expression. Cell Struct Funct.
44:29–39. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hu R, Zhu X, Chen C, Xu R, Li Y and Xu W:
RNA-binding protein PUM2 suppresses osteosarcoma progression via
partly and competitively binding to STARD13 3′UTR with miRNAs. Cell
Prolif. 51:e125082018. View Article : Google Scholar : PubMed/NCBI
|
